- Home
- CADL vs ZTR Comparison
CADL vs ZTR Comparison
Compare CADL & ZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- ZTR
- Stock Information
- Founded
- CADL 1999
- ZTR 1988
- Country
- CADL United States
- ZTR Australia
- Employees
- CADL N/A
- ZTR N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- ZTR Investment Managers
- Sector
- CADL Health Care
- ZTR Finance
- Exchange
- CADL Nasdaq
- ZTR Nasdaq
- Market Cap
- CADL 339.8M
- ZTR 350.0M
- IPO Year
- CADL 2021
- ZTR N/A
- Fundamental
- Price
- CADL $5.60
- ZTR $6.52
- Analyst Decision
- CADL Strong Buy
- ZTR
- Analyst Count
- CADL 7
- ZTR 0
- Target Price
- CADL $19.57
- ZTR N/A
- AVG Volume (30 Days)
- CADL 852.2K
- ZTR 219.4K
- Earning Date
- CADL 11-13-2025
- ZTR 01-01-0001
- Dividend Yield
- CADL N/A
- ZTR 12.09%
- EPS Growth
- CADL N/A
- ZTR N/A
- EPS
- CADL N/A
- ZTR N/A
- Revenue
- CADL N/A
- ZTR N/A
- Revenue This Year
- CADL N/A
- ZTR N/A
- Revenue Next Year
- CADL N/A
- ZTR N/A
- P/E Ratio
- CADL N/A
- ZTR N/A
- Revenue Growth
- CADL N/A
- ZTR N/A
- 52 Week Low
- CADL $3.79
- ZTR $4.50
- 52 Week High
- CADL $14.60
- ZTR $6.60
- Technical
- Relative Strength Index (RSI)
- CADL 50.83
- ZTR 52.76
- Support Level
- CADL $5.11
- ZTR $6.49
- Resistance Level
- CADL $5.52
- ZTR $6.61
- Average True Range (ATR)
- CADL 0.39
- ZTR 0.07
- MACD
- CADL -0.04
- ZTR -0.01
- Stochastic Oscillator
- CADL 32.89
- ZTR 33.33
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.